Clinical characteristics and survival of Korean idiopathic pulmonary arterial hypertension patients based on vasoreactivity.

Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci (2015) 0.85

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J (2009) 14.06

Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05

Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2013) 8.29

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med (1992) 6.40

Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98

Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57

Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2003) 2.23

Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest (2007) 2.19

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14

Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J (2009) 1.67

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis (1989) 1.16

Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest (2013) 1.10

Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly (2008) 1.06

Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. J Korean Med Sci (2012) 0.93

Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest (1997) 0.91

Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease. J Korean Med Sci (2013) 0.80

Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. Intern Med (2012) 0.78

A Case of IgG4-Related Lung Disease Presenting as Interstitial Lung Disease. Tuberc Respir Dis (Seoul) (2014) 0.88

Three-month treatment response and exacerbation in chronic obstructive pulmonary disease. J Korean Med Sci (2014) 0.77

Causes and predictive factors associated with "diagnosis changed" outcomes in patients notified as tuberculosis cases in a private tertiary hospital. Tuberc Respir Dis (Seoul) (2013) 0.76

Assessment Of Changes In Regional Xenon-Ventilation, Perfusion, And Ventilation-Perfusion Mismatch Using Dual-Energy Computed Tomography After Pharmacological Treatment In Patients With Chronic Obstructive Pulmonary Disease: Visual And Quantitative Analysis. Int J Chron Obstruct Pulmon Dis (2019) 0.75